London Regenerative Aesthetics: Standards Checklist

Use this checklist to assess whether a London regenerative-aesthetics business has identified the applicable product route, premises controls, supplier evidence and records. It distinguishes statutory duties from useful procurement controls. Local licensing and product classification depend on the activity, route and facts, so each item requires documentary verification rather than assumption.

How to use this checklist

This is a document-review checklist for a buyer, operator or procurement reviewer assessing a regenerative-aesthetics service in London. It is not a list of treatments, an assessment of clinical suitability, or a finding that a particular product or activity is lawful. Tick an item only when the relevant current document is available, identifiable and applicable to the activity being reviewed.

The central question is not whether a product is described with a fashionable label. It is what the item is, what is done to it, how it is supplied, what is said it does, and how it is used. Those facts determine which legal and operational controls may apply. A supplier brochure, a certificate of analysis and a trade name may be useful supporting material, but none independently settles classification.

1. □ Define the activity in one neutral sentence. Record the material, its source, its physical form, the route of use, whether the skin is intact, the setting and the intended purpose. Why it matters: classification and local controls turn on facts, not on the umbrella term “regenerative”. Source or standard: the Medicines and Healthcare products Regulatory Agency explains that borderline decisions depend on the individual product and its intended purpose.
2. □ Separate legal requirements from internal controls. Mark each remaining item as statutory, regulator guidance, local-authority condition, contractual requirement or voluntary quality control. Why it matters: this prevents a supplier preference being presented as a legal obligation. Source or standard: the Health and Safety Executive distinguishes legal duties under health and safety law from guidance on meeting them.
3. □ Date every document. Note version, issue date, owner and review date, particularly for regulatory correspondence and local licences. Why it matters: classification positions and local conditions can change. Source or standard: the MHRA publishes regulatory guidance that is subject to revision, while London boroughs administer local licensing arrangements.

A completed checklist should preserve the evidence reviewed and any uncertainty. “Not applicable” needs a short reason. “Not evidenced” is not the same as “compliant”.

Product status and regulatory route

A regenerative-aesthetics review starts with product status, not promotional terminology. In the United Kingdom, a product may fall within medicines law, medical devices law, human-tissue controls, general product rules, or more than one framework at different points in its supply chain. The applicable route cannot safely be inferred from a label such as exosome, secretome, biologic, cell-free or research use.

4. □ Obtain the supplier’s written classification rationale. It should identify the product, intended purpose, route of administration, legal manufacturer where relevant, and the framework the supplier says applies. Why it matters: a short assertion of compliance does not show the reasoning or its scope. Source or standard: the MHRA is the UK authority that provides guidance on medicines, medical devices and borderline products.
5. □ Check whether the supplied intended purpose matches the planned activity. Compare labelling, instructions, packaging and supplier documentation with the actual route and setting. Why it matters: changing route, preparation or stated purpose may alter the regulatory analysis and invalidate reliance on supplied documentation. Source or standard: the MHRA’s borderline-product approach considers intended purpose and presentation.
6. □ Escalate unclear cases to the appropriate regulator or specialist legal advice. Keep a written record of the question asked, material supplied and answer received. Why it matters: classification is fact-specific, and a checklist cannot make a binding determination. Source or standard: the MHRA gives regulatory information for products at the boundary between medicines and other categories.
7. □ Check human-origin material separately. Establish whether donation, procurement, testing, processing, storage or distribution creates duties under the human-tissue framework. Why it matters: human-origin sourcing raises traceability and consent questions distinct from final-product marketing. Source or standard: the Human Tissue Authority regulates activities within its remit under the Human Tissue Act 2004 and related legislation.

Do not treat a research designation as a shortcut through the classification question. Its significance depends on the exact product, documentation and supply arrangement. Keep supplier claims separate from a regulator’s view.

London premises and activity controls

London does not have one universal aesthetics licence. Borough councils have separate responsibilities, and local conditions can differ. The London Local Authorities Act 1991 provides a licensing framework for specified special treatments in London, but whether a particular activity needs a licence depends on the treatment, the premises, local implementation and the facts. A checklist should therefore identify the borough before asking whether a licence exists.

8. □ Identify the London borough and the exact premises address. Check the council’s current special-treatment licensing information and conditions, then retain the relevant page or correspondence in the compliance file. Why it matters: a licence or condition in one borough is not evidence of the position in another. Source or standard: the relevant London borough council administers its local licensing process under the London Local Authorities Act 1991.
9. □ Map the actual activity against local licence categories. Record every procedure and device used, rather than selecting a broad business category. Why it matters: the statutory special-treatment categories and local interpretation may not align with commercial descriptions. Source or standard: the London Local Authorities Act 1991 sets out special-treatment licensing provisions.
10. □ Check that the premises documentation matches the operating model. Review occupancy permission, local licence where applicable, insurance evidence and written operating procedures. Why it matters: moving rooms, changing procedures or using a visiting operator can create a mismatch between paperwork and practice. Source or standard: applicable borough licence conditions are the primary source for local premises requirements.
11. □ Assess whether any regulated healthcare activity is being carried on. Do not assume that a cosmetic setting is outside registration rules, or that a clinical title proves registration. Why it matters: registration with the Care Quality Commission is tied to regulated activities, not to branding. Source or standard: the Care Quality Commission regulates providers that carry on regulated activities in England.

Where the activity sits near a boundary, obtain a written local or regulatory view rather than relying on informal comparison with another premises.

Quality, traceability and supplier records

A buyer should be able to reconstruct what arrived, from whom, in which batch, under what conditions, and with which instructions. This is a supply-chain test, not an outcome claim. A certificate of analysis may confirm specified tests for a batch, but it does not by itself establish lawful classification, suitability for a particular use, or consistency across batches.

12. □ Reconcile product identity across all documents. Match product name, batch or lot number, manufacturer or supplier identity, quantity, storage instruction and expiry or retest information. Why it matters: mismatched identifiers break traceability. Source or standard: ISO 9001 addresses documented control of processes and identification where needed for conformity, although certification to ISO 9001 is not a product approval.
13. □ Read the certificate of analysis as a limited batch record. Check the tested attributes, methods, acceptance criteria, date, laboratory identity and authorised signatory where supplied. Record what it does not test. Why it matters: particle count, protein measure or marker result alone cannot describe every quality attribute. Source or standard: the International Society for Extracellular Vesicles’ MISEV guidance describes the need for transparent reporting and multiple characterisation considerations in extracellular-vesicle research.
14. □ Preserve storage and receipt evidence. Record dispatch condition, receipt date, observed package condition, storage environment and any excursion reported by the supplier. Why it matters: a batch document cannot retrospectively prove that handling after release followed instructions. Source or standard: the Health and Safety Executive requires employers to control workplace risks, and supplier handling instructions define the product-specific conditions claimed.
15. □ Create a withdrawal and incident trail. Keep supplier contact routes, batch distribution records, complaints, deviations and actions taken. Why it matters: traceability is useful only if affected stock and records can be identified quickly. Source or standard: the MHRA operates safety-reporting systems within its regulatory remit; the appropriate route depends on product status.

Terms such as GMP and ISO should be read precisely. Ask what site, process, scope and certificate are covered. They do not automatically certify every product attribute or every intended use.

Workplace safety, infection control and waste

Operational controls apply regardless of whether an activity is described as innovative. The employer or person controlling the work must consider foreseeable hazards, the competence of workers, cleaning arrangements, sharps and waste. A supplier’s technical sheet may identify hazards, but it does not replace a workplace risk assessment.

16. □ Complete a written risk assessment for the actual work. Include biological exposure, sharps, cleaning agents, cold storage, spill response and staff roles where relevant. Why it matters: generic policies can miss the risks created by a particular premises and workflow. Source or standard: the Health and Safety at Work etc. Act 1974 and the Management of Health and Safety at Work Regulations 1999 establish core employer duties on health and safety management.
17. □ Check hazardous-substances controls where substances may create risk. Retain safety information and document control measures, training and emergency arrangements. Why it matters: handling and cleaning exposures need an evidenced control approach. Source or standard: the Control of Substances Hazardous to Health Regulations 2002 require assessment and control of hazardous-substance risks.
18. □ Verify sharps and waste arrangements. Identify segregation, containers, collection arrangements and the person responsible for each stage. Why it matters: waste handling is a separate operational chain, not an afterthought to a procedure. Source or standard: the Health and Safety Executive publishes guidance on preventing sharps injuries; waste duties are administered through environmental regulation.
19. □ Record staff training and competence for assigned tasks. Keep role-specific training records, supervision arrangements and review dates. Why it matters: a qualification title alone does not document competence for every local process. Source or standard: the Health and Safety Executive expects employers to provide information, instruction, training and supervision necessary for health and safety.

This checklist does not prescribe a clinical protocol. It tests whether the operator can show a proportionate, documented system for managing the work environment.

Information governance and evidence boundaries

Regenerative-aesthetics records can contain personal data, health information, images, supplier documents and incident notes. The evidence review should distinguish data protection duties from quality records, and it should avoid treating consent as a universal solution. The lawful basis, transparency information, security and retention approach need their own documentation.

20. □ Map the personal data being collected. List contact data, photographs, health information, appointment records, communications and supplier-held data. Why it matters: data cannot be governed properly if it has not been identified. Source or standard: the Information Commissioner’s Office explains the accountability principle under the UK GDPR.
21. □ Identify the lawful basis and any condition for special-category data. Document the reasoning and provide appropriate privacy information. Why it matters: health data receives additional protection under the UK GDPR. Source or standard: the Information Commissioner’s Office provides guidance on lawful bases and special-category data.
22. □ Check processor arrangements and security controls. Where a booking, record or image service processes data for the organisation, retain the required contractual and security documentation. Why it matters: outsourcing storage does not remove accountability. Source or standard: the Information Commissioner’s Office explains controller and processor responsibilities under the UK GDPR.
23. □ Grade every evidence statement before relying on it. Separate supplier material, laboratory work, animal work and human research; record whether the item concerns the same material, route and outcome. Why it matters: evidence about a related product is not automatically evidence about the product under review. Source or standard: the International Society for Extracellular Vesicles promotes transparent reporting of extracellular-vesicle research.

For patient-facing treatment decisions, consult exosomestherapy.co.uk. This reference is limited to product, documentation and operational assessment.

Limits, exclusions and final sign-off

This checklist is for document-led assessment in London. It does not give legal advice, make a regulatory classification, determine whether an individual should receive a treatment, assess clinical competence, or replace a regulator, local authority, lawyer, qualified health-and-safety adviser or data-protection specialist. It does not apply a single answer to all boroughs, products, routes or business models.

24. □ Produce a one-page exception register. For every unverified or escalated item, state the missing document, owner, risk, interim control and review date. Why it matters: a long folder of records can conceal unresolved issues. Source or standard: the Health and Safety Executive’s risk-management approach requires action to control identified risks.
25. □ Obtain accountable sign-off. Name the person who reviewed classification, premises, supply, safety and data items, and record what they did not verify. Why it matters: sign-off should identify responsibility without pretending certainty beyond the evidence. Source or standard: the Information Commissioner’s Office describes accountability as an active obligation under the UK GDPR.
26. □ Set a re-review trigger. Review when the supplier, source material, process, route, premises, local licence condition, regulator guidance or data processor changes. Why it matters: compliance evidence is tied to facts at a point in time. Source or standard: the MHRA, local authorities and the Information Commissioner’s Office each publish guidance and requirements that may be updated.

The useful output is not a generic “compliant” label. It is a dated file that identifies which requirements were verified, which were inapplicable, and which require a decision from the body with authority to make it.